Riskpilot← Back to searchSign inGet full accessColumnakliniken vid Odenplan AB
ABActiveOrg 5591234470Sturegatan 18Physiotherapy activities · NACE 8695Est. 20171 employees
Revenue 2025
SEK 691K
-49% vs 2024
EBITDA margin
-43.4%
+13% vs 2024
Equity ratio
-65.5%
Financial strength
Net profit 2025
SEK -314K
+14% vs 2024
| Revenue | SEK 691K | -49% |
| EBITDA | SEK -300K | +13% |
| Net profit | SEK -314K | +14% |
| Total assets | SEK 358K | -44% |
| Equity | SEK -234K | -392% |
| Employees | 1 | — |
Legal name
Columnakliniken vid Odenplan AB
Org number
5591234470
Legal form
Aktiebolag
NACE code
8695 · Physiotherapy activities
Founded
31 augusti 2017
Share capital
SEK 50 000
Employees
1 (FTE)
VAT registered
No
Audit selected
No
Last report
2025-08-31
Financial year
January – December
Signatory rights
Firman tecknas var för sig av ledamoten suppleanten
Company purpose
Bolaget skall bedriva rehabilitering, friskvård, skadeförebyggande behandling, utbildning samt försäljning av produkter hänförliga till verksamheten.
Address
Sturegatan 18
Email
jonas@naprapat.net
Risika for professionals
Risika provides regulated workflow tools for finance, procurement and compliance teams that need monitoring, alerts and an API.
| Item | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|
| Revenue | 1 596 | 2 797 | 2 769 | 1 365 | 691 |
| Staff expenses | — | −794 | −918 | −636 | −372 |
| EBITDA | 12 | 383 | 409 | −343 | −300 |
| Depreciation & amort. | −8 | −7 | −7 | — | — |
| EBIT | 4 | 375 | 402 | −343 | −300 |
| Net financials | — | −0 | −12 | −22 | −14 |
| Profit before tax | 3 | 289 | 6 | −365 | −314 |
| Tax | −0 | −53 | −2 | — | — |
| Net profit | 3 | 235 | 3 | −365 | −314 |
| Item | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|
| Total assets | 619 | 916 | 1 041 | 638 | 358 |
| Equity | 56 | 292 | 295 | 80 | −234 |
| Long-term debt | 0 | — | — | — | — |
| Short-term debt | 562 | 537 | 746 | 558 | 592 |
| Total debt | 562 | 537 | 746 | 558 | 592 |
EBITDA margin
-43.4%
This company
15.8%
Market median
-375% vs market
20212025
Equity ratio
-65.5%
This company
38.2%
Market median
-271% vs market
20212025
Return on equity
-31433500.0%
This company
18.4%
Market median
-170834339% vs market
20212025
Net profit margin
-45.5%
This company
8.1%
Market median
-662% vs market
20212025
Asset turnover
1.93×
This company
1.12×
Market median
+72% vs market
20212025
Debt / equity
2.53×
This company
0.62×
Market median
-308% vs market
20212025
- Annual report 2025Filed via Bolagsverket / SCB · Period 2024-09-01 – 2025-08-31
- Annual report 2024Filed via Bolagsverket / SCB · Period 2023-09-01 – 2024-08-31
- Annual report 2023Filed via Bolagsverket / SCB · Period 2022-09-01 – 2023-08-31
- Annual report 2022Filed via Bolagsverket / SCB · Period 2021-09-01 – 2022-08-31
- Annual report 2021Filed via Bolagsverket / SCB · Period 2020-09-01 – 2021-08-31
| Name | Role | Member since |
|---|---|---|
| Current (1) | ||
CH Chief Executive Officer | Chief Executive Officer | 2022 |
| Name | Role | Member since |
|---|---|---|
| Current (1) | ||
| Deputy Board Member | 2022 | |
| Shareholder | Type | Ownership | Votes | Since |
|---|---|---|---|---|
| Company | 100% | 100% | 0001 |
Beneficial ownership (UBO) data access is restricted in Denmark as of September 2025 per the EU 6th AML Directive. Learn more.
No registered parent or subsidiaries
Board members of Columnakliniken vid Odenplan AB also hold positions in 0 other companies.
| Person | Role here | Other companies |
|---|---|---|
| Claes Henning Jonas Hård af Segerstad | Chief Executive Officer | 0 companies |
| Elisabeth Cecilia Blomberg | Deputy Board Member | 0 companies |